PTC Therapeutics filings document a Delaware biopharmaceutical company with common stock listed on the Nasdaq Global Select Market under PTCT. Its Form 8-K reports cover quarterly and annual financial results, Regulation FD disclosures, product and pipeline updates, FDA-related communications, and board or compensation matters.
Proxy materials describe annual meeting governance, director elections, executive compensation, equity awards and related shareholder matters. The filing record also includes disclosures tied to rare-disease programs such as Sephience™ (sepiapterin), votoplam and Translarna™ (ataluren), along with the company’s capital structure and public-company reporting obligations.
PTCT holders sold common stock in multiple transactions disclosed on Form 144. The excerpt lists sale lots by Neil G. Almstead and Zheng Y. Almstead between 01/06/2026 and 02/18/2026, including examples of 1,279 shares for $98,415.98 and 3,056 shares for $211,953.77.
The entries show routine dispositions tied to restricted stock vesting and ESPP purchases in prior years; amounts and prices are itemized per sale date.
Lee S. Golden reported sales of common stock under Rule 144. The filing shows sales of 1,340 shares on 01/06/2026 for $103,109.78, 642 shares on 01/07/2026 for $49,744.60, 866 shares on 01/08/2026 for $66,204.92, and 2,484 shares on 02/18/2026 for $172,281.80.
The filing also lists multiple prior restricted stock vesting entries issued by the company on various dates, including vesting quantities such as 1,287 on 01/09/2023 and 1,885 on 01/05/2024, shown as background to the sold securities.
PTC Therapeutics executive Mark Elliott Boulding, Executive VP and Chief Legal Officer, reported open-market sales of a total of 3,019 shares of common stock on February 19, 2026. The transactions, executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 4, 2024, occurred at weighted-average prices of $68.54 and $69.82 per share, based on multiple trades within disclosed price ranges from $67.99 to $70.18. Following these sales, Boulding directly held 105,212 shares of PTC Therapeutics common stock.
PTC Therapeutics SVP and Chief Accounting Officer Christine Marie Utter reported an automatic sale of 2,494 shares of common stock. The shares were sold at an average price of $69.36 per share to cover tax withholding obligations tied to recently vested restricted stock units.
These shares relate to the vesting of 3,500 RSUs from a February 15, 2024 grant of 14,000 RSUs and 1,450 RSUs from a February 15, 2024 grant of 2,900 RSUs. After this tax-withholding sale, Utter directly holds 70,199 shares of PTC Therapeutics common stock.
PTC Therapeutics chief financial officer Pierre Gravier reported an automatic sale of 2,992 shares of common stock at $69.36 per share. After this transaction, he holds 87,318 shares directly. The shares were sold under an irrevocable sell-to-cover instruction to satisfy tax withholding on recently vested restricted stock units (RSUs) from prior grants.
PTC Therapeutics, Inc.'s chief business officer, Eric Pauwels, reported an automatic sale of 3,019 shares of common stock in an open-market transaction at a price of $69.36 per share. The sale was made under an irrevocable sell-to-cover election to satisfy tax withholding obligations upon the vesting of previously granted RSUs.
After this transaction, Pauwels directly holds 77,122 shares of PTC Therapeutics common stock. The sale reflects tax-related withholding rather than a discretionary reduction of his overall equity position.
PTC Therapeutics, Inc. reported that Chief Executive Officer Matthew B. Klein automatically sold 7,371 shares of common stock at an average price of $69.36 per share. The sale was made under an irrevocable sell-to-cover election to satisfy tax withholding on the vesting of 17,500 restricted stock units from a February 15, 2025 grant of 70,000 RSUs. Following this tax-related sale, Klein owned 387,082 shares of PTC Therapeutics common stock directly.
PTC Therapeutics EVP & Chief Medical Officer Lee Scott Golden reported an automatic sale of 2,484 shares of common stock. The shares were sold on February 18, 2026 in open-market transactions at a price of $69.36 per share.
According to the filing, the sale was executed under an irrevocable "sell to cover" election to satisfy tax withholding obligations tied to the vesting of previously granted restricted stock units (RSUs). After this transaction, Golden directly holds 89,944 shares of PTC Therapeutics common stock.
PTC Therapeutics chief technical operations officer Neil Gregory Almstead reported automatic stock sales to cover taxes tied to restricted stock unit vesting. On February 18, he sold 3,121 shares of common stock at $69.36 per share, including 3,056 shares held directly and 65 shares held indirectly through his spouse.
These transactions were executed under irrevocable sell-to-cover elections made when the RSU grants were accepted, to satisfy tax withholding obligations. After these sales, Almstead held 112,140 shares directly and 6,726 shares indirectly through his spouse.
PTC Therapeutics executive Mark Elliott Boulding reported option exercises and share sales. On February 17, 2026, he exercised stock options for 2,813 shares of common stock at $25.69 per share, increasing his direct common stock holdings to 114,125 shares.
On February 17–18, 2026, he sold a total of 5,894 shares of common stock in open-market transactions at prices around $69.29–$70.13 per share, pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on December 4, 2024. A portion of the shares sold was automatically sold to cover tax withholding obligations related to vesting restricted stock units. After these transactions, he directly owned 108,231 shares of common stock and 22,501 stock options that are currently exercisable.